



Functional Nanocarrier Technology to Deliver siRNA for Cancer Therapy

Guest Editors:

Prof. Dr. Daisuke Ishibashi

Department of Immunological
and Molecular Pharmacology,
Faculty of Pharmaceutical
Science, Fukuoka University, 8-
19-1 Nanakuma Jonan-ku,
Fukuoka, Japan

Dr. Mai Hazekawa

Department of Immunological
and Molecular Pharmacology,
Faculty of Pharmaceutical
Science, Fukuoka University, 8-
19-1 Nanakuma Jonan-ku,
Fukuoka, Japan

Deadline for manuscript
submissions:

closed (10 March 2022)

Message from the Guest Editors

Nucleic acid medicines, including antisense oligonucleotides, small interfering RNA (siRNA), aptamers, and locked nucleic acids, have the potential to therapeutically regulate gene expressions. In recent years, new drugs for genetic diseases have been developed and are attracting a great deal of attention. However, these strategies are limited to treating localized diseases so far. That is why further development of drug delivery systems (DDSs) is essential for the clinical application of nucleic acid medicine to apply cancer treatment.

To address this challenging issue, we focus on development of DDSs to deliver siRNA for cancer therapy, and we will clarify the usefulness of cancer treatment by target gene regulation using nucleic acid medicine designed by functional nanocarrier.

This Special Issue will highlight the development of DDSs using functional nanocarriers to deliver siRNA for cancer therapy. We also expect to discuss the possibility of developing novel nanocarrier design with added value to conventional technology.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma